ALAN W DUNTON
CIK 1304773 · Chief Exec Officer & President · last filed 2026-01-27
ALAN W DUNTON is a Chief Exec Officer & President who has filed 118 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for CRMD, was dated Jan 27, 2026. Across all open-market trades the lifetime net is +$3.6M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $914.1K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$914.1K
6
118
$3.59M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRMD | Director | 70,703 | $8.74 | $617.9K | -$338.3K | 16 | 2026-01-27 |
| OGEN | Director | 25,623 | $0.62 | $15.9K | -$186.7K | 28 | 2025-12-15 |
| PTN | Director | 20,601 | $13.61 | $280.3K | $4.02M | 32 | 2025-12-11 |
| MNOV | Director | — | $1.23 | — | $0 | 4 | 2010-06-15 |
| PANACOS PHARMACEUTICALS, INC. (PANC) Delisted | Chief Exec Officer & President | 240,865 | — | — | $96.3K | 8 | 2008-05-05 |
| Adams Respiratory Therapeutics, Inc. (ARXT) Delisted | Director | 0 | — | — | $0 | 7 | 2008-01-30 |
Recent Filings
118 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-01-27 | CRMD | Grant (A) | +30,453 | $0 | EDGAR |
| 2026-01-02 | CRMD | Mixed | — | -$179.4K | EDGAR |
| 2025-12-15 | OGEN | Grant (A) | — | $0 | EDGAR |
| 2025-12-11 | PTN | Grant (A) | +2,000 | $0 | EDGAR |
| 2025-09-16 | CRMD | Mixed | — | -$95.8K | EDGAR |
| 2025-06-17 | PTN | Buy (P) | +200 | $4.00M | EDGAR |
| 2025-01-22 | CRMD | Grant (A) | +25,000 | $0 | EDGAR |
| 2024-12-09 | OGEN | Sell (S) | −66 | -$24 | EDGAR |
| 2024-09-20 | OGEN | Grant (A) | — | $0 | EDGAR |
| 2024-07-17 | PTN | Grant (A) | +12,000 | $0 | EDGAR |